BioNTech hat vereinbart, den ehemaligen Corona-Impfstoffkonkurrenten CureVac für rund 1,25 Milliarden Dollar (1,08 Milliarden ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

The major averages were mixed near noon with the Dow the laggard as a pullback in Boeing weighs on the Industrials index. U.S ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The Trump administration had said it would disclose by Wednesday the target prices for drugs, but pharma companies are still ...

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its ...